Unlocking the True Potential of CRISPR Cas9 Gene Editing!

Europe's #1 event for addressing CRISPR's application challenges

AstraZeneca and Novartis have turned to CRISPR for drug discovery, have you?

2015 has seen an increasing percentage of pharmaceutical companies implement CRISPR technologies into their drug discovery plans.

Earlier this year Novartis' Institute for BioMedical Research (NIBR) President Mark Fishman stated "we have glimpsed the power of CRISPR tools in our scientific programs in NIBR, and it is now time to explore how to safely extend this powerful technology to the clinic."*

AstraZeneca have announced four research collaborations aimed at harnessing the power of CRISPR, and GlaxoSmithKline is leading a $64 million investment for CRISPR Therapeutics.

There is no doubt about it, CRISPR is rapidly changing the way diseases are researched, and will soon revolutionise the way they are treated.

Whether you are already underway with using CRISPR in your research, or are considering implementing the technology, this conference will provide you with all the information you need to harness CRISPR’s true potential.

In preparation for the event, we invite you to take part in a short online study to evaluate current and future usage of CRISPR for various applications. The results will then be provided to you, so that you can compare your responses to those of your peers. Please click this link to go to the survey, or copy and paste the link www.surveymonkey.com/r/CRISPRsurvey into your internet browser.

For the first time in Europe, Pharma IQ is bringing together key industry leaders to introduce you to the CRISPR revolution, and help you address the specificity, efficiency and delivery challenges preventing you from making the most of the CRISPR technology. Take a look at the agenda, view our full speaker line-up of CRISPR founders and industry-leading experts, or go straight ahead and book your place now.

Download Agenda

2015 Speakers Included:

View All Speakers

Don't miss out on:

 

A keynote address from the Zhang Lab’s Jonathan Gootenberg, who will share his experience working with Feng Zhang to discover the Cpf1 protein, and what this discovery means for the future of gene editing

 

Discovering the latest tools, technologies and techniques in CRISPR application from the Doudna Lab’s Sam Sternberg, who has been working closely with Jennifer Doudna to optimize the CRISPR technique

 

Learning how to rapidly and accurately identify drug targets with true potential from experts from AstraZeneca who are using CRISPR in drug discovery and screening

 

Discovering how Takeda are using CRISPR to stimulate homologous recombination for driving large genome alterations in recalcitrant cell lines

 

Hearing as yet unpublished data from Dr William Skarnes of the Wellcome Trust Sanger Institute as part of our extensive line up of case studies from CRISPR pioneers

Praise for previous Pharma IQ events:


Media Partners